Finally, a recent small trial Assessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction (ASSAIL-MI) (n = 199) showed that tocilizumab, an inhibitor of the inflammatory cytokine interleukin-6 (IL-6) pathway, which is a downstream effector of IL-1β, increased the extent of myocardial recovery after reperfusion when compared with matching placebo [63••]. The gene discussed is IL6; the disease is myocardial infarction.